Global Diagnostic Biomarkers
Global Diagnostic Biomarkers

Diagnostic Biomarkers Comprehensive Study by Type (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers), Application (Hospitals, Cancer Research Institutes, Diagnostic Labs), Biomarkers validated Method (Natural history markers, Drug activity markers, Surrogate markers), Biomarkers (Exposure, Effect, Susceptibility) Players and Region - Global Market Outlook to 2025

Diagnostic Biomarkers Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Feb 2020 Edition 238 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Diagnostic Biomarkers Market Overview:
Diagnostic Biomarkers are basically used for conforming that patient has a particular health disorder. A kind of test that is used to diagnose a disease, is often measures a type of biomarker which is called a “surrogate." Diagnostic biomarkers facilitate earlier detection of a disorder than can be achieved by physical examination of a patient. While the word Biomarkers are definite biological indicators that is cellular, biochemical or molecular of a process, or condition which is been measured reliably in tissues, cells or fluids, and it can also be used to detect early changes in a patient’s health. Some of the key players profiled in the study are Qiagen N.V. (Netherlands), Perkinelmer, Inc. (United States), Merck Millipore (United States), Bio-Rad Laboratories, Inc. (United States), Enzo Biochem, Inc. (United States), EKF Diagnostics Holdings, Inc. (United Kingdom), Meso Scale Diagnostics, LLC. (United States), Biosims Technologies Sas (France), Cisbio Bioassays (France) and Signosis, Inc (United States).

On the basis of geography, the market of Diagnostic Biomarkers has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Biomarkers validated Method, the sub-segment i.e. Natural history markers will boost the Diagnostic Biomarkers market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Biomarkers , the sub-segment i.e. Exposure will boost the Diagnostic Biomarkers market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing prevalence of various kind of disorder
  • Increasing instances of depression, attention deficit and disruptive behavior disorders

Market Trend
  • Increasing advances in areas such as biomarker discovery and microfluidic device fabrication
  • Technological advancement in field of genetics

Restraints
  • Various issues related to regulatory and reimbursement systems
  • Comparatively higher costs associated with vocal diagnostic biomarkers

Opportunities
  • Growing research and development in medical related treatment

Challenges
  • A dearth of skilled professionals in the field of medical
  • Technical issues related to accuracy and electronics components



The FDA’s Center for Devices and Radiological Health (CDRH) conducts research to support science-based and transparent decisions and minimize assumptions and subjectivity in the device review process. FDA scientists advance regulatory science by developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of medical devices.
The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market in the near future. Players are anticipated to focus on the development of new compounds, which is likely to encourage the growth of the global market throughout the forecast period.

Target Audience:
Global diagnostic biomarkers, manufacturers & suppliers, Research and development (R&D) companies, Market research and consulting service providers, Academic institutes and universities, Government Agencies and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Diagnostic Biomarkers market on the basis of product [Safety Biomarkers, Efficacy Biomarkers and Validation Biomarkers] , application [Hospitals, Cancer Research Institutes and Diagnostic Labs], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Diagnostic Biomarkers market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Diagnostic Biomarkers industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Banyan Biomarkers, Inc (United States) and Response Biomedical Corporation (Canada).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Diagnostic Biomarkers market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Type
  • Safety Biomarkers
  • Efficacy Biomarkers
  • Validation Biomarkers
By Application
  • Hospitals
  • Cancer Research Institutes
  • Diagnostic Labs
By Biomarkers validated Method
  • Natural history markers
  • Drug activity markers
  • Surrogate markers

By Biomarkers
  • Exposure
  • Effect
  • Susceptibility

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing prevalence of various kind of disorder
      • 3.2.2. Increasing instances of depression, attention deficit and disruptive behavior disorders
    • 3.3. Market Challenges
      • 3.3.1. A dearth of skilled professionals in the field of medical
      • 3.3.2. Technical issues related to accuracy and electronics components
    • 3.4. Market Trends
      • 3.4.1. Increasing advances in areas such as biomarker discovery and microfluidic device fabrication
      • 3.4.2. Technological advancement in field of genetics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Diagnostic Biomarkers, by Type, Application, Biomarkers validated Method, Biomarkers and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Diagnostic Biomarkers (Value)
      • 5.2.1. Global Diagnostic Biomarkers by: Type (Value)
        • 5.2.1.1. Safety Biomarkers
        • 5.2.1.2. Efficacy Biomarkers
        • 5.2.1.3. Validation Biomarkers
      • 5.2.2. Global Diagnostic Biomarkers by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Cancer Research Institutes
        • 5.2.2.3. Diagnostic Labs
      • 5.2.3. Global Diagnostic Biomarkers by: Biomarkers validated Method (Value)
        • 5.2.3.1. Natural history markers
        • 5.2.3.2. Drug activity markers
        • 5.2.3.3. Surrogate markers
      • 5.2.4. Global Diagnostic Biomarkers Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Diagnostic Biomarkers: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Qiagen N.V. (Netherlands)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Perkinelmer, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck Millipore (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bio-Rad Laboratories, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Enzo Biochem, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. EKF Diagnostics Holdings, Inc. (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Meso Scale Diagnostics, LLC. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biosims Technologies Sas (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cisbio Bioassays (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Signosis, Inc (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Diagnostic Biomarkers Sale, by Type, Application, Biomarkers validated Method, Biomarkers and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Diagnostic Biomarkers (Value)
      • 7.2.1. Global Diagnostic Biomarkers by: Type (Value)
        • 7.2.1.1. Safety Biomarkers
        • 7.2.1.2. Efficacy Biomarkers
        • 7.2.1.3. Validation Biomarkers
      • 7.2.2. Global Diagnostic Biomarkers by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Cancer Research Institutes
        • 7.2.2.3. Diagnostic Labs
      • 7.2.3. Global Diagnostic Biomarkers by: Biomarkers validated Method (Value)
        • 7.2.3.1. Natural history markers
        • 7.2.3.2. Drug activity markers
        • 7.2.3.3. Surrogate markers
      • 7.2.4. Global Diagnostic Biomarkers Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Diagnostic Biomarkers: by Type(USD Million)
  • Table 2. Diagnostic Biomarkers Safety Biomarkers , by Region USD Million (2014-2019)
  • Table 3. Diagnostic Biomarkers Efficacy Biomarkers , by Region USD Million (2014-2019)
  • Table 4. Diagnostic Biomarkers Validation Biomarkers , by Region USD Million (2014-2019)
  • Table 5. Diagnostic Biomarkers: by Application(USD Million)
  • Table 6. Diagnostic Biomarkers Hospitals , by Region USD Million (2014-2019)
  • Table 7. Diagnostic Biomarkers Cancer Research Institutes , by Region USD Million (2014-2019)
  • Table 8. Diagnostic Biomarkers Diagnostic Labs , by Region USD Million (2014-2019)
  • Table 9. Diagnostic Biomarkers: by Biomarkers validated Method(USD Million)
  • Table 10. Diagnostic Biomarkers Natural history markers , by Region USD Million (2014-2019)
  • Table 11. Diagnostic Biomarkers Drug activity markers , by Region USD Million (2014-2019)
  • Table 12. Diagnostic Biomarkers Surrogate markers , by Region USD Million (2014-2019)
  • Table 13. South America Diagnostic Biomarkers, by Country USD Million (2014-2019)
  • Table 14. South America Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 15. South America Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 16. South America Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 17. South America Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 18. Brazil Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 19. Brazil Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 20. Brazil Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 21. Brazil Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 22. Argentina Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 23. Argentina Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 24. Argentina Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 25. Argentina Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 26. Rest of South America Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 27. Rest of South America Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 28. Rest of South America Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 29. Rest of South America Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 30. Asia Pacific Diagnostic Biomarkers, by Country USD Million (2014-2019)
  • Table 31. Asia Pacific Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 32. Asia Pacific Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 33. Asia Pacific Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 34. Asia Pacific Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 35. China Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 36. China Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 37. China Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 38. China Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 39. Japan Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 40. Japan Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 41. Japan Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 42. Japan Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 43. India Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 44. India Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 45. India Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 46. India Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 47. South Korea Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 48. South Korea Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 49. South Korea Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 50. South Korea Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 51. Taiwan Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 52. Taiwan Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 53. Taiwan Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 54. Taiwan Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 55. Australia Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 56. Australia Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 57. Australia Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 58. Australia Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 59. Rest of Asia-Pacific Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 60. Rest of Asia-Pacific Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 61. Rest of Asia-Pacific Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 62. Rest of Asia-Pacific Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 63. Europe Diagnostic Biomarkers, by Country USD Million (2014-2019)
  • Table 64. Europe Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 65. Europe Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 66. Europe Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 67. Europe Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 68. Germany Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 69. Germany Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 70. Germany Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 71. Germany Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 72. France Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 73. France Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 74. France Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 75. France Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 76. Italy Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 77. Italy Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 78. Italy Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 79. Italy Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 80. United Kingdom Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 81. United Kingdom Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 82. United Kingdom Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 83. United Kingdom Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 84. Netherlands Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 85. Netherlands Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 86. Netherlands Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 87. Netherlands Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 88. Rest of Europe Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 89. Rest of Europe Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 90. Rest of Europe Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 91. Rest of Europe Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 92. MEA Diagnostic Biomarkers, by Country USD Million (2014-2019)
  • Table 93. MEA Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 94. MEA Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 95. MEA Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 96. MEA Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 97. Middle East Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 98. Middle East Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 99. Middle East Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 100. Middle East Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 101. Africa Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 102. Africa Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 103. Africa Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 104. Africa Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 105. North America Diagnostic Biomarkers, by Country USD Million (2014-2019)
  • Table 106. North America Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 107. North America Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 108. North America Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 109. North America Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 110. United States Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 111. United States Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 112. United States Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 113. United States Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 114. Canada Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 115. Canada Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 116. Canada Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 117. Canada Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 118. Mexico Diagnostic Biomarkers, by Type USD Million (2014-2019)
  • Table 119. Mexico Diagnostic Biomarkers, by Application USD Million (2014-2019)
  • Table 120. Mexico Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2014-2019)
  • Table 121. Mexico Diagnostic Biomarkers, by Biomarkers USD Million (2014-2019)
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Diagnostic Biomarkers: by Type(USD Million)
  • Table 133. Diagnostic Biomarkers Safety Biomarkers , by Region USD Million (2020-2025)
  • Table 134. Diagnostic Biomarkers Efficacy Biomarkers , by Region USD Million (2020-2025)
  • Table 135. Diagnostic Biomarkers Validation Biomarkers , by Region USD Million (2020-2025)
  • Table 136. Diagnostic Biomarkers: by Application(USD Million)
  • Table 137. Diagnostic Biomarkers Hospitals , by Region USD Million (2020-2025)
  • Table 138. Diagnostic Biomarkers Cancer Research Institutes , by Region USD Million (2020-2025)
  • Table 139. Diagnostic Biomarkers Diagnostic Labs , by Region USD Million (2020-2025)
  • Table 140. Diagnostic Biomarkers: by Biomarkers validated Method(USD Million)
  • Table 141. Diagnostic Biomarkers Natural history markers , by Region USD Million (2020-2025)
  • Table 142. Diagnostic Biomarkers Drug activity markers , by Region USD Million (2020-2025)
  • Table 143. Diagnostic Biomarkers Surrogate markers , by Region USD Million (2020-2025)
  • Table 144. South America Diagnostic Biomarkers, by Country USD Million (2020-2025)
  • Table 145. South America Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 146. South America Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 147. South America Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 148. South America Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 149. Brazil Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 150. Brazil Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 151. Brazil Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 152. Brazil Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 153. Argentina Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 154. Argentina Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 155. Argentina Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 156. Argentina Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 157. Rest of South America Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 158. Rest of South America Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 159. Rest of South America Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 160. Rest of South America Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 161. Asia Pacific Diagnostic Biomarkers, by Country USD Million (2020-2025)
  • Table 162. Asia Pacific Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 163. Asia Pacific Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 164. Asia Pacific Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 165. Asia Pacific Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 166. China Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 167. China Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 168. China Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 169. China Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 170. Japan Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 171. Japan Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 172. Japan Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 173. Japan Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 174. India Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 175. India Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 176. India Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 177. India Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 178. South Korea Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 179. South Korea Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 180. South Korea Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 181. South Korea Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 182. Taiwan Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 183. Taiwan Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 184. Taiwan Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 185. Taiwan Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 186. Australia Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 187. Australia Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 188. Australia Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 189. Australia Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 190. Rest of Asia-Pacific Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 191. Rest of Asia-Pacific Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 192. Rest of Asia-Pacific Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 193. Rest of Asia-Pacific Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 194. Europe Diagnostic Biomarkers, by Country USD Million (2020-2025)
  • Table 195. Europe Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 196. Europe Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 197. Europe Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 198. Europe Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 199. Germany Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 200. Germany Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 201. Germany Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 202. Germany Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 203. France Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 204. France Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 205. France Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 206. France Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 207. Italy Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 208. Italy Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 209. Italy Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 210. Italy Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 211. United Kingdom Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 212. United Kingdom Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 213. United Kingdom Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 214. United Kingdom Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 215. Netherlands Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 216. Netherlands Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 217. Netherlands Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 218. Netherlands Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 219. Rest of Europe Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 220. Rest of Europe Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 221. Rest of Europe Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 222. Rest of Europe Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 223. MEA Diagnostic Biomarkers, by Country USD Million (2020-2025)
  • Table 224. MEA Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 225. MEA Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 226. MEA Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 227. MEA Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 228. Middle East Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 229. Middle East Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 230. Middle East Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 231. Middle East Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 232. Africa Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 233. Africa Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 234. Africa Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 235. Africa Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 236. North America Diagnostic Biomarkers, by Country USD Million (2020-2025)
  • Table 237. North America Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 238. North America Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 239. North America Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 240. North America Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 241. United States Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 242. United States Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 243. United States Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 244. United States Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 245. Canada Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 246. Canada Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 247. Canada Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 248. Canada Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 249. Mexico Diagnostic Biomarkers, by Type USD Million (2020-2025)
  • Table 250. Mexico Diagnostic Biomarkers, by Application USD Million (2020-2025)
  • Table 251. Mexico Diagnostic Biomarkers, by Biomarkers validated Method USD Million (2020-2025)
  • Table 252. Mexico Diagnostic Biomarkers, by Biomarkers USD Million (2020-2025)
  • Table 253. Research Programs/Design for This Report
  • Table 254. Key Data Information from Secondary Sources
  • Table 255. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Diagnostic Biomarkers: by Type USD Million (2014-2019)
  • Figure 5. Global Diagnostic Biomarkers: by Application USD Million (2014-2019)
  • Figure 6. Global Diagnostic Biomarkers: by Biomarkers validated Method USD Million (2014-2019)
  • Figure 7. South America Diagnostic Biomarkers Share (%), by Country
  • Figure 8. Asia Pacific Diagnostic Biomarkers Share (%), by Country
  • Figure 9. Europe Diagnostic Biomarkers Share (%), by Country
  • Figure 10. MEA Diagnostic Biomarkers Share (%), by Country
  • Figure 11. North America Diagnostic Biomarkers Share (%), by Country
  • Figure 12. Global Diagnostic Biomarkers share by Players 2019 (%)
  • Figure 13. Global Diagnostic Biomarkers share by Players (Top 3) 2019(%)
  • Figure 14. Global Diagnostic Biomarkers share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Qiagen N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 17. Qiagen N.V. (Netherlands) Revenue: by Geography 2019
  • Figure 18. Perkinelmer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Perkinelmer, Inc. (United States) Revenue: by Geography 2019
  • Figure 20. Merck Millipore (United States) Revenue, Net Income and Gross profit
  • Figure 21. Merck Millipore (United States) Revenue: by Geography 2019
  • Figure 22. Bio-Rad Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Bio-Rad Laboratories, Inc. (United States) Revenue: by Geography 2019
  • Figure 24. Enzo Biochem, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Enzo Biochem, Inc. (United States) Revenue: by Geography 2019
  • Figure 26. EKF Diagnostics Holdings, Inc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. EKF Diagnostics Holdings, Inc. (United Kingdom) Revenue: by Geography 2019
  • Figure 28. Meso Scale Diagnostics, LLC. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Meso Scale Diagnostics, LLC. (United States) Revenue: by Geography 2019
  • Figure 30. Biosims Technologies Sas (France) Revenue, Net Income and Gross profit
  • Figure 31. Biosims Technologies Sas (France) Revenue: by Geography 2019
  • Figure 32. Cisbio Bioassays (France) Revenue, Net Income and Gross profit
  • Figure 33. Cisbio Bioassays (France) Revenue: by Geography 2019
  • Figure 34. Signosis, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 35. Signosis, Inc (United States) Revenue: by Geography 2019
  • Figure 36. Global Diagnostic Biomarkers: by Type USD Million (2020-2025)
  • Figure 37. Global Diagnostic Biomarkers: by Application USD Million (2020-2025)
  • Figure 38. Global Diagnostic Biomarkers: by Biomarkers validated Method USD Million (2020-2025)
  • Figure 39. South America Diagnostic Biomarkers Share (%), by Country
  • Figure 40. Asia Pacific Diagnostic Biomarkers Share (%), by Country
  • Figure 41. Europe Diagnostic Biomarkers Share (%), by Country
  • Figure 42. MEA Diagnostic Biomarkers Share (%), by Country
  • Figure 43. North America Diagnostic Biomarkers Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Qiagen N.V. (Netherlands)
  • Perkinelmer, Inc. (United States)
  • Merck Millipore (United States)
  • Bio-Rad Laboratories, Inc. (United States)
  • Enzo Biochem, Inc. (United States)
  • EKF Diagnostics Holdings, Inc. (United Kingdom)
  • Meso Scale Diagnostics, LLC. (United States)
  • Biosims Technologies Sas (France)
  • Cisbio Bioassays (France)
  • Signosis, Inc (United States)
Additional players considered in the study are as follows:
Banyan Biomarkers, Inc (United States) , Response Biomedical Corporation (Canada)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation